Detalles de la búsqueda
1.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate
; 84(3): 292-302, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37964482
2.
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
Eur Urol
; 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38644146
3.
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
Eur Urol Oncol
; 2024 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38523017
4.
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.
JAMA Netw Open
; 6(8): e2326546, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37526936
5.
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).
J Urol
; 188(4): 1164-9, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22921015
6.
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
J Clin Oncol
; 40(28): 3301-3309, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35446628
7.
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Prostate Cancer Prostatic Dis
; 24(2): 558-566, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33420417
8.
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Clin Cancer Res
; 27(7): 1967-1973, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33500355
9.
Addressing apoptosis to tumor zip codes.
Cancer
; 121(14): 2296-9, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25832592
10.
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
J Urol
; 181(6): 2476-80; discussion 2480-1, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19371909
11.
Inflammatory Bowel Disease and the Risk of Prostate Cancer.
Eur Urol
; 75(5): 846-852, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30528221
12.
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Cancer
; 112(11): 2393-400, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18383517
13.
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Clin Genitourin Cancer
; 6(2): 103-9, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18824433
14.
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
N Engl J Med
; 351(15): 1513-20, 2004 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-15470214
15.
Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
JAMA Oncol
; 3(11): e170231, 2017 Nov 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28358937
16.
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.
Clin Genitourin Cancer
; 15(6): 635-641, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28579151
17.
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
J Clin Oncol
; 23(15): 3562-7, 2005 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-15908667
18.
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.
Urology
; 77(5): 1172-6, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21334731
19.
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.
J Clin Oncol
; 29(15): 2040-5, 2011 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21502546
20.
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.
Clin Cancer Res
; 16(11): 3028-34, 2010 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20484019